{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:50:58Z","timestamp":1792173058055,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40262-022-01197-0","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T10:03:15Z","timestamp":1673517795000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria"],"prefix":"10.1007","volume":"62","author":[{"given":"Megan","family":"Melch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongtae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jomphe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"3","key":"1197_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","volume":"128","author":"JD Phillips","year":"2019","unstructured":"Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164\u201377.","journal-title":"Mol Genet Metab"},{"key":"1197_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.715523","volume":"15","author":"PVS de Souza","year":"2021","unstructured":"de Souza PVS, Badia BML, Farias IB, Pinto W, Oliveira ASB. Acute hepatic porphyria: pathophysiological basis of neuromuscular manifestations. Front Neurosci. 2021;15: 715523.","journal-title":"Front Neurosci"},{"issue":"5","key":"1197_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","volume":"36","author":"G Elder","year":"2013","unstructured":"Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849\u201357.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"1197_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","volume":"142","author":"KE Anderson","year":"2005","unstructured":"Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439\u201350.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14218\/JCTH.2014.00039","volume":"3","author":"DM Bissell","year":"2015","unstructured":"Bissell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3(1):17\u201326.","journal-title":"J Clin Transl Hepatol"},{"key":"1197_CR6","unstructured":"GIVLAARI (givosiran) injection, for subcutaneous use [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; 2021."},{"key":"1197_CR7","unstructured":"GIVLAARI - Summary of Product Characteristics. Amsterdam: Alnylam Netherlands B.V.; 2021."},{"issue":"24","key":"1197_CR8","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, Peiro PA, Rees DC, Stolzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289\u2013301.","journal-title":"N Engl J Med"},{"issue":"1","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/liv.15090","volume":"42","author":"P Ventura","year":"2022","unstructured":"Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiro P, Montgomery Bissell D, Stein PE, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022;42(1):161\u201372.","journal-title":"Liver Int"},{"issue":"6","key":"1197_CR10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa1807838","volume":"380","author":"E Sardh","year":"2019","unstructured":"Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"1197_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpt.1802","volume":"108","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Simon AR, Goel V, Habtemariam BA, Clausen VA, Kim JB, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63\u201372.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1197_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1124\/dmd.121.000381","volume":"49","author":"J Li","year":"2021","unstructured":"Li J, Liu J, Zhang X, Clausen V, Tran C, Arciprete M, et al. Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion of givosiran, the first approved n-acetylgalactosamine-conjugated RNA interference therapeutic. Drug Metab Dispos. 2021;49(7):572\u201380.","journal-title":"Drug Metab Dispos"},{"issue":"49","key":"1197_CR13","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958\u201361.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"1197_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1124\/dmd.121.000428","volume":"50","author":"R McDougall","year":"2022","unstructured":"McDougall R, Ramsden D, Agarwal S, Agarwal S, Aluri K, Arciprete M, et al. The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab Dispos. 2022;50(6):781\u201397.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1197_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"1197_CR16","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function\u2014Study Design, Data Analysis, and Impact on Dosing. Spring Hill, MD: CDER; 2020."},{"issue":"5","key":"1197_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2337\/diacare.15.11.1484","volume":"15","author":"JP Vora","year":"1992","unstructured":"Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992;15(11):1484\u201393.","journal-title":"Diabetes Care"},{"issue":"7","key":"1197_CR19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ekir.2021.04.004","volume":"6","author":"H Lazareth","year":"2021","unstructured":"Lazareth H, Poli A, Bignon Y, Mirmiran A, Rabant M, Cohen R, et al. Renal function decline with small interfering RNA silencing aminolevulinic acid synthase 1 (ALAS1). Kidney Int Rep. 2021;6(7):1904\u201311.","journal-title":"Kidney Int Rep."},{"issue":"12","key":"1197_CR20","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3390\/diagnostics11122324","volume":"11","author":"A Ricci","year":"2021","unstructured":"Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney involvement in acute hepatic porphyrias: Pathophysiology and diagnostic implications. Diagnostics (Basel). 2021;11(12):2324.","journal-title":"Diagnostics (Basel)."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01197-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01197-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:44:40Z","timestamp":1675442680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01197-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01197-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"7 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was sponsored by Alnylam Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Megan Melch, Jongtae Lee, and Gabriel Robbie are Alnylam Pharmaceutical employees and may hold Alnylam stocks or options. Claudia Jomphe is an employee of Certara Strategic Consulting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All study protocols received Institutional Review Board or Ethics Committee approval and were conducted in accordance with the principles of the International Conference on Harmonisation Good Clinical Practice guidelines, the World Health Organization Declaration of Helsinki, and the 1996 Health Insurance Portability and Accountability Act.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All study participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"De-identified individual participant data access\u00a0will be provided contingent upon the approval of a research proposal and execution of a data sharing agreement. Requests for access to data can be submitted via the website .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Gabriel J. Robbie was\u00a0involved in the conception and design of the study. All authors were involved in the\u00a0analysis and interpretation of the data, critical review of manuscript drafts, and approval of the submitted manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}